Halozyme to Host Third Quarter Financial Results Conference Call

       Halozyme to Host Third Quarter Financial Results Conference Call

PR Newswire

SAN DIEGO, Nov. 1, 2012

SAN DIEGO, Nov. 1, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:
HALO) will webcast its Quarterly Update Conference Call for the third quarter
2012 on Thursday, November 8, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I.
Frost, President and Chief Executive Officer, will lead the call. On the same
date post-market, Halozyme will release financial results for the third
quarter 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's
corporate website and a recording will be made available following the close
of the call. To access the webcast, please log on to www.halozyme.com
approximately fifteen minutes prior to the call to register, download and
install any necessary audio software. For those without access to the
Internet, the live call may be accessed by phone by calling (877) 407-8037
(domestic callers) or (201) 689-8037 (international callers). A telephone
replay will be available shortly after the call by dialing (877) 660-6853
(domestic callers) or (201) 612-7415 (international callers) using replay ID
number 402796.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing
and commercializing innovative products that advance patient care. With a
diversified portfolio of enzymes that target the extracellular matrix, the
Company's research focuses primarily on a family of human enzymes, known as
hyaluronidases, that increase the absorption and dispersion of biologics.
Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology
and dermatology that have significant unmet medical need. The Company markets
HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with
Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San
Diego, CA. For more information on how we are innovating, please visit our
corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics

SOURCE Halozyme Therapeutics, Inc.

Website: http://www.halozyme.com
Press spacebar to pause and continue. Press esc to stop.